Dynavax Technologies’ (DVAX) Outperform Rating Reaffirmed at William Blair
Dynavax Technologies (NASDAQ:DVAX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by William Blair in a note issued to investors on Friday,RTT News reports. William Blair also issued ...
Dynavax price target raised to $33 from $29 at Citizens JMP
Citizens JMP raised the firm’s price target on Dynavax (DVAX) to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported ...
Dynavax Technologies climbs as investor begins proxy fight (update)
Dynavax Technologies (NASDAQ:DVAX) rose 2.8% after a large investor started a proxy fight with the vaccine maker. Deep Track ...
Exclusive: Investor Deep Track launches proxy fight at Dynavax, nominates 4 directors
Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies , pressing for new directors to prioritize the development of the company's hepatitis B vaccine ...
JMP Securities Keeps Their Buy Rating on Dynavax (DVAX)
JMP Securities analyst Jason Butler reiterated a Buy rating on Dynavax (DVAX – Research Report) today and set a price target of $33.00. The ...
Business Wire4d
Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies’ Board of Directors at 2025 Annual Meeting
Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NAS ...
Dynavax projects HEPLISAV-B revenue of $305M-$325M for 2025 amid expanding hepatitis B market
Q4 2024 Management View CEO Ryan Spencer highlighted the company’s record HEPLISAV-B product revenue in Q4 and 2024, achieving profitability and implementing a share repurchase plan. Looking ahead, ...
Dynavax sees FY25 adjusted EBITDA ‘at least $75M’ vs. $51.9M in FY24
HEPLISAV-B net product revenue is expected in the range of $305M to $325M Discover the Best Stocks and Maximize Your Portfolio: See what ...